Genotype prevalence, viral load and outcome of hepatitis B virus precore mutant infection in stable patients and in patients after liver transplantation

Ben‐Ari, Ziv; Ashur, Yaffa; Daudi, Nili; Shmilovitz-Wiess, Hemda; Brown, Marius; Sulkes, Jaqueline; Klein, Andreas; Mor, Eytan; Tur–Kaspa, Ran

doi:10.1111/j.1399-0012.2004.00182.x

Cited by 17 publications

(12 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HBV can be classified into eight genotypes (A–H) (17, 18). In our experience in the Mediterranean basin, the predominant genotype is D (96%) (19). HBV genotypes may affect the rate of recovery after acute infection, the progression of chronic liver disease, and the response to antiviral treatment.…”

Section: Discussionmentioning

confidence: 75%

Lamivudine treatment for acute severe hepatitis B: a pilot study

Schmilovitz‐Weiss

Ben‐Ari

Sikuler

et al. 2004

Liver International

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 75%

Lamivudine treatment for acute severe hepatitis B: a pilot study

Schmilovitz‐Weiss

Ben‐Ari

Sikuler

et al. 2004

Liver International

View full text Add to dashboard Cite

show abstract

“…Ben-Ari et al (Table 8) reported no statistically significant difference in genotype prevalence in patients undergoing liver transplantation and stable patients. 112 Girlanda et al (Table 8) reported that genotypes A and D were not significant predictors of transplantation outcomes. 61 Tables 4 and 8 summarize the clinical implications and correlation between HBV genotypes and liver transplantation outcomes.…”

Section: Liver Transplantationmentioning

confidence: 97%

Hepatitis B virus genotyping: current methods and clinical implications

Guirgis

Abbas

Azzazy

2010

International Journal of Infectious Diseases

View full text Add to dashboard Cite

Hepatitis B virus (HBV) is a major cause of liver cirrhosis and hepatocellular carcinoma (HCC). Eight different HBV genotypes have been identified with distinct geographical distributions. Different genotyping methods exist including sequencing, INNO-LiPA, restriction fragment polymorphism (RFLP), multiplex PCR, serotyping, oligonucleotide microarray chips, reverse dot blot, restriction fragment mass polymorphism (RFMP), invader assay, and real-time PCR. Several investigators have studied the influence of HBV genotypes on clinical outcomes in chronic HBV patients. This review describes the current genotyping techniques, as well as their advantages and limitations. It also presents the clinical evidence that correlates HBV genotypes to clinical outcomes including disease severity, HCC development, response to therapy, disease chronicity, transplantation outcomes, and occult infection.

show abstract

“…Different HBV genotype on recurrence rate have been discussed, but as shown in two recent studies, difference in the recurrence rate between different HBV genotypes were not observed [15,16].…”

Section: Hbv Reinfection After Oltmentioning

confidence: 96%

Prophylaxis and treatment of recurrent viral hepatitis after liver transplantation

Riediger

Berberat

Sauer

et al. 2007

Nephrology Dialysis Transplantation

View full text Add to dashboard Cite

Chronic hepatitis B or C can cause severe liver diseases such as liver cirrhosis and hepatocellular carcinoma (HCC). Both viral infections together especially hepatitis c virus infection (HCV) are the mayor indication for liver transplantation in Western Europe and the United States. Recurrence of hepatitis B virus (HBV) or HCV infection after orthotopic liver transplantation (OLT) plays a key role for the outcome after liver transplantation concerning patient and graft survival rates. Allograft dysfunctions, cirrhosis of the allograft and graft failure are major complications after recurrent viral hepatitis. The survival after liver transplantation for HBV-related liver disease changed dramatically during the last two decades with results today comparable with non-HBV-related liver transplantations. Availability of immunoprophylaxis with hepatitis B immunoglobulin (HBIG) as well as nucleoside/nucleotide analogues like lamivudine or adefovir in the pre- and post-transplant setting conferred to significant better results due to an efficient prophylaxis and the possibility of therapy of HBV reinfection of the allograft. New drugs such as entecavir, tenofovir and telbivudine for the treatment of chronic hepatitis B infections may offer even more opportunities in the transplant setting. In contrast, despite recent achievements in the treatment of HCV infection with pegylated interferons and ribavirin, patients with HCV cirrhosis or after liver transplantation are difficult to treat. Sustained virological response (SVR) rates in prophylactic and therapeutic approaches of HCV reinfection after OLT are only low compared to the pre-cirrhotic HCV infection. Moreover, best treatment duration and dosage of recurrent HCV infection with pegylated interferon in combination with ribavirin remains to be defined.

show abstract

Genotype prevalence, viral load and outcome of hepatitis B virus precore mutant infection in stable patients and in patients after liver transplantation

Cited by 17 publications

References 40 publications

Lamivudine treatment for acute severe hepatitis B: a pilot study

Lamivudine treatment for acute severe hepatitis B: a pilot study

Hepatitis B virus genotyping: current methods and clinical implications

Prophylaxis and treatment of recurrent viral hepatitis after liver transplantation

Contact Info

Product

Resources

About